The CRA framework's indicative assessment topics reveal the weighting. Study the framework document itself — downloadable from the GPhC website.
High-weight (60-70%): Cardiovascular (hypertension per NICE NG136, heart failure per NG185, AF per NG208, ACS). CNS (depression, epilepsy, Parkinson's, pain management, anxiolytics/hypnotics). Endocrine (diabetes T1/T2, thyroid disorders). Respiratory (asthma, COPD — NICE/BTS guidelines). Infections (antibiotics by indication, antifungals, antivirals).
Medium-weight: GI (PPIs, IBD, antiemetics). MSK (gout, RA, osteoporosis). Renal (AKI, CKD, dose adjustments). Dermatology (eczema, psoriasis, acne).
Lower-weight but tested: Palliative care, ophthalmology, ENT, sexual health.
Cross-cutting themes that appear in every therapeutic area: Drug interactions. Adverse effects. Monitoring requirements. Prescribing in special populations — pregnancy, breastfeeding, elderly, paediatric, renal impairment, hepatic impairment.
Strategy: Weeks 1-4 on high-weight (maximise score floor). Weeks 5-6 on medium-weight and law. Weeks 7-8 on review, gaps, and mocks.
iatroX's adaptive quiz automatically weights revision toward your weak therapeutic areas — if you are strong on cardiovascular but weak on CNS, it shifts your question mix accordingly.